AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16093415 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy (CIMT)
Number of subjects: 26
Study 16093415 — intervention group
Group type: EXPERIMENTAL
Intervention: Pairwise therapy
Number of subjects: 26
Study 12116728 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100 ppm sodium fluoride dentifrice
Number of subjects: 1334
Study 10442360 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT plus oral calcium folinate
Number of subjects: 473
Study 10442360 — intervention group
Group type: COMPARATOR
Intervention: 5-FU plus calcium folinate
Number of subjects: 473
Study 7844595 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intramuscular ASNase (25,000 IU/m2) weekly (n = 8)
Number of subjects: 20
Study 7844595 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose intramuscular ASNase (10,000 IU/m2) every 3 days (n = 12)
Number of subjects: 20
Study 2332001 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D echo-Doppler (ED)
Number of subjects: 56
Study 2332001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac catheterization (CATH)
Number of subjects: 56
Study 367433 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pindolol
Number of subjects: 6
Study 367433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pindolol
Number of subjects: 6
Study 31060917 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB) combined with Posterior Capsular Infiltration (PCI)
Number of subjects: 0
Study 31060917 — intervention group
Group type: COMPARATOR
Intervention: Multimodal periarticular infiltration analgesia
Number of subjects: 0
Study 28584014 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability in systolic blood pressure (SBP)
Number of subjects: 9114
Study 26303187 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression bandaging (CB) and physical exercises
Number of subjects: 60
Study 26303187 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex decongestive therapy (CDT) including Vodder II Manual Lymph Drainage
Number of subjects: 60
Study 26303187 — intervention group
Group type: COMPARATOR
Intervention: Both groups (CB and CDT)
Number of subjects: 60
Study 23903526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 70
Study 23903526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 21340560 — intervention group
Group type: EXPERIMENTAL
Intervention: Provox HME®
Number of subjects: 60
Study 21340560 — intervention group
Group type: COMPARATOR
Intervention: Control group (no device)
Number of subjects: 60
Study 18651150 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D isotropic MRI T2‐weighted sequence (3D T2 ISO)
Number of subjects: 53
Study 18651150 — intervention group
Group type: COMPARATOR
Intervention: 2D TSE T2‐weighted sequence (2D T2)
Number of subjects: 53
Study 18651150 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with IIEF‐5 score using 3D T2 ISO
Number of subjects: 53
Study 17114146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Masking (TM)
Number of subjects: 123
Study 17114146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Retraining Therapy (TRT)
Number of subjects: 123
Study 14756231 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched Air Nitrox 36% (oxygen 36%, nitrogen 64%)
Number of subjects: 11
Study 14756231 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 11
Study 10371376 — intervention group
Group type: COMPARATOR
Intervention: Normal sodium diet (235 mEq/day)
Number of subjects: 8
Study 10371376 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate salt restriction (75 mEq/day)
Number of subjects: 8
Study 8964113 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g)
Number of subjects: 0
Study 8964113 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamin C (2 g) and vitamin E (100 and 800 U)
Number of subjects: 0
Study 8964113 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 0
Study 8964113 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (3 weeks)
Number of subjects: 0
Study 1803141 — intervention group
Group type: EXPERIMENTAL
Intervention: Endonasal calcitrin (3 units twice a day for 1-1.5 months)
Number of subjects: 0
Study 1803141 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular calcitrin (not specified)
Number of subjects: 0
Study 6438672 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10-160 mg)
Number of subjects: 0
Study 6438672 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (30-480 mg)
Number of subjects: 0
Study 6438672 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (160 mg)
Number of subjects: 0
Study 31203202 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention cohort (toolkit implemented)
Number of subjects: 107
Study 31203202 — intervention group
Group type: COMPARATOR
Intervention: Historic cohort (no intervention)
Number of subjects: 107
Study 29322164 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (0.1 mg/d) plus intermittent micronized progesterone (200 mg/d for 12 days every 3 months)
Number of subjects: 172
Study 29322164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 29322164 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol plus intermittent micronized progesterone (TE+IMP)
Number of subjects: 172
Study 26703413 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based educational intervention (50-minute workshop on speaking up)
Number of subjects: 71
Study 26703413 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 71
Study 24248549 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid lag screws
Number of subjects: 45
Study 24248549 — intervention group
Group type: EXPERIMENTAL
Intervention: Telescoping screws
Number of subjects: 45
Study 22103635 — intervention group
Group type: EXPERIMENTAL
Intervention: SumaRT/Nap (85mg sumatriptan and 500mg naproxen sodium)
Number of subjects: 442
Study 22103635 — intervention group
Group type: EXPERIMENTAL
Intervention: BCM (50mg butalbital, 325mg acetaminophen, 40mg caffeine)
Number of subjects: 442
Study 22103635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study 20017668 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic therapy
Number of subjects: 0
Study 20017668 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical cohort analysis and prospective clinical intervention studies
Number of subjects: 0
Study 20017668 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of pharmacogenomic therapy into practice
Number of subjects: 0
Study 17577005 — intervention group
Group type: COMPARATOR
Intervention: Adjusted-dose warfarin (6 trials, 2900 participants)
Number of subjects: 28044
Study 17577005 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet agents (8 trials, 4876 participants)
Number of subjects: 28044
Study 17577005 — intervention group
Group type: COMPARATOR
Intervention: Adjusted-dose warfarin (12 trials, 12,963 participants)
Number of subjects: 28044
Study 17577005 — intervention group
Group type: COMPARATOR
Intervention: Antithrombotic therapy (general)
Number of subjects: 28044
Study 15829425 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus acidophilus and Bifidobacterium bifidum) from day 1 to day 15
Number of subjects: 30
Study 15829425 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus acidophilus and Bifidobacterium bifidum) from day 8 to day 15 after placebo from day 1 to day 7
Number of subjects: 30
Study 15829425 — intervention group
Group type: COMPARATOR
Intervention: Placebo from day 1 to day 15
Number of subjects: 30
Study 15829425 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo from day 1 to day 7 and probiotics from day 8 to day 15
Number of subjects: 30
Study 12477523 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Number of subjects: 52
Study 12477523 — intervention group
Group type: COMPARATOR
Intervention: Triptorelin
Number of subjects: 52
Study 10091511 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 micrograms formoterol via Turbohaler
Number of subjects: 99
Study 10091511 — intervention group
Group type: COMPARATOR
Intervention: 50 micrograms salmeterol via Diskus
Number of subjects: 99
Study 10091511 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 micrograms formoterol Turbohaler b.i.d.
Number of subjects: 99
Study 10091511 — intervention group
Group type: COMPARATOR
Intervention: 50 micrograms salmeterol Diskus b.i.d.
Number of subjects: 99
Study 7759224 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 12
Study 2672936 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomeride plus diet
Number of subjects: 1315
Study 2672936 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus diet
Number of subjects: 1315
Study 708998 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal diet with 100 mmol supplementary sodium chloride
Number of subjects: 12
Study 708998 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal diet with 96 mmol supplementary potassium chloride
Number of subjects: 12
Study 708998 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 12
Study 30987577 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative urinary NGAL at 48 hours >156ng/mL
Number of subjects: 125
Study 30987577 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary NGAL concentrations at 24 hours
Number of subjects: 125
Study 30987577 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary NGAL concentrations at 48 hours
Number of subjects: 125
Study 30987577 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary NGAL concentrations at 72 hours
Number of subjects: 125
Study 30987577 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary NGAL concentrations at 96 hours
Number of subjects: 125
Study 30987577 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier plot for survival
Number of subjects: 125
Study 30987577 — intervention group
Group type: EXPERIMENTAL
Intervention: Additive EuroSCORE, age, current smoking, and post-operative antibiotics usage
Number of subjects: 125
Study 27940512 — intervention group
Group type: EXPERIMENTAL
Intervention: Announcement training
Number of subjects: 17173
Study 27940512 — intervention group
Group type: COMPARATOR
Intervention: Conversation training
Number of subjects: 17173
Study 27940512 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 17173
Study 25599932 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC AUC
Number of subjects: 0
Study 25599932 — intervention group
Group type: EXPERIMENTAL
Intervention: Net benefit methods
Number of subjects: 0
Study 23998375 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS (1.5 mg/ml)
Number of subjects: 24
Study 23998375 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone graft
Number of subjects: 24
Study 21390978 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio pillow with hypnosis text and relaxation music (n = 44)
Number of subjects: 82
Study 21390978 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 20082245 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Chinese drugs (Shengmai Injection by intravenous dripping and Gujin Granule by oral intake) plus Navelbine and Cisplatin (NP) chemotherapy
Number of subjects: 63
Study 20082245 — intervention group
Group type: COMPARATOR
Intervention: Navelbine and Cisplatin (NP) chemotherapy alone
Number of subjects: 63
Study 20082245 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Chinese drugs (Shengmai Injection and Gujin Granule) plus NP chemotherapy
Number of subjects: 63
Study 17908569 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 17
Study 17908569 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (invasive sham)
Number of subjects: 17
Study 17908569 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Acupuncture and Sham acupuncture
Number of subjects: 17
Study 15541450 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 107
Study 15541450 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 107
Study 15541450 — intervention group
Group type: COMPARATOR
Intervention: Tetracosactide
Number of subjects: 107
Study 11985183 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased certainty (90% chance of developing AD)
Number of subjects: 449
Study 11985183 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased certainty (50% chance of developing AD)
Number of subjects: 449
Study 9385493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/d (30 patients with 37 lesions)
Number of subjects: 70
Study 9385493 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 81 mg/d (40 patients with 45 lesions)
Number of subjects: 70
Study 7944044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass procedures with GI complications
Number of subjects: 64
Study 7944044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass procedures with longer pump and cross-clamp times
Number of subjects: 64
Study 7944044 — intervention group
Group type: EXPERIMENTAL
Intervention: Redo procedures
Number of subjects: 64
Study 7944044 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of an intra-aortic balloon pump
Number of subjects: 64
Study 7944044 — intervention group
Group type: EXPERIMENTAL
Intervention: GI complications
Number of subjects: 64
Study 2688781 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 120
Study 2688781 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 120
Study 2688781 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pimozide and lithium
Number of subjects: 120
Study 2688781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 57914 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of gamma globulin
Number of subjects: 148
Study 57914 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of gamma globulin
Number of subjects: 148
Study 57914 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated)
Number of subjects: 148
Study 30790529 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 43
Study 30790529 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid capsules
Number of subjects: 43
Study 24794767 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete compromise (Group A)
Number of subjects: 44
Study 24794767 — intervention group
Group type: COMPARATOR
Intervention: Incomplete compromise (Group B)
Number of subjects: 44
Study 22612302 — intervention group
Group type: COMPARATOR
Intervention: Double plateletpheresis (DP)
Number of subjects: 411
Study 22612302 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple plateletpheresis (TP)
Number of subjects: 411
Study 21599896 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathlessness Intervention Service (BIS)
Number of subjects: 0
Study 21599896 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 19144148 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training at 80% of peak strength, progressing 3% per session, 3 days per week for 6 months.
Number of subjects: 0
Study 19144148 — intervention group
Group type: COMPARATOR
Intervention: Sham-exercise group (completed all exercises except hip adduction, without added resistance or progression).
Number of subjects: 0
Study 22879633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (diet and physical activity)
Number of subjects: 680
Study 22879633 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice a day
Number of subjects: 680
Study 22879633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 680
Study 22879633 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen users
Number of subjects: 680
Study 22879633 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-estrogen users
Number of subjects: 680
Study 16018774 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (group I)
Number of subjects: 100
Study 16018774 — intervention group
Group type: COMPARATOR
Intervention: No epidural analgesia (group II)
Number of subjects: 100
Study 16018774 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (group III, non-pre-eclamptic)
Number of subjects: 100
Study 16018774 — intervention group
Group type: COMPARATOR
Intervention: No epidural analgesia (group IV, normotensive)
Number of subjects: 100
Study 12358384 — intervention group
Group type: EXPERIMENTAL
Intervention: Training sessions in the Neer system
Number of subjects: 14
Study 12358384 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 14
Study 12358384 — intervention group
Group type: EXPERIMENTAL
Intervention: Training sessions for specialists
Number of subjects: 14
Study 9709932 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐AG (500 mg daily)
Number of subjects: 12
Study 9709932 — intervention group
Group type: EXPERIMENTAL
Intervention: DL‐AG (1000 mg daily)
Number of subjects: 12
Study 7659431 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)‐ketamine
Number of subjects: 23
Study 7659431 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)‐ketamine
Number of subjects: 23
Study 7659431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (unspecified form)
Number of subjects: 23
Study 2228629 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) for active tuberculosis patients
Number of subjects: 205
Study 2228629 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) for preventive therapy patients
Number of subjects: 205
Study 369921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclazindol (50 mg b.d.)
Number of subjects: 35
Study 369921 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (50 mg b.d.)
Number of subjects: 35
Study 11249050 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with cisplatin 100 mg/m2 on day 1 and vinorelbine 30 mg/m2 on days 1, 8, 15, 22, with cycles repeated every four weeks (arm A)
Number of subjects: 176
Study 11249050 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with cisplatin and vinorelbine plus early WBRT 30 Gy/10 fx/12 days (arm B)
Number of subjects: 176
Study 11249050 — intervention group
Group type: COMPARATOR
Intervention: Delayed WBRT (arm A)
Number of subjects: 176
Study 11249050 — intervention group
Group type: COMPARATOR
Intervention: Early WBRT (arm B)
Number of subjects: 176
Study 11249050 — intervention group
Group type: COMPARATOR
Intervention: Both arms (A and B)
Number of subjects: 176
Study 30073688 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned vaginal delivery
Number of subjects: 1435
Study 30073688 — intervention group
Group type: COMPARATOR
Intervention: Planned cesarean delivery
Number of subjects: 1435
Study 29421247 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine pain screening
Number of subjects: 60
Study 27788820 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler echocardiography (DE)
Number of subjects: 103
Study 27788820 — intervention group
Group type: COMPARATOR
Intervention: Right heart catheterization (RHC)
Number of subjects: 103
Study 24760002 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent conjugate vaccine (PCV7) followed by 23-valent polysaccharide vaccine (23vPPV) 6 months later
Number of subjects: 312
Study 24760002 — intervention group
Group type: COMPARATOR
Intervention: 23-valent polysaccharide vaccine (23vPPV) alone
Number of subjects: 312
Study 24760002 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 312
Study 22528535 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG treatment on day 0, 1, and 2 (Group III)
Number of subjects: 40
Study 22528535 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG treatment on days 0 and 1 (Group II)
Number of subjects: 40
Study 22528535 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG treatment on day 0 (Group I)
Number of subjects: 40
Study 22528535 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 22528535 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG treatment (all groups)
Number of subjects: 40
Study 21400792 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with bupivacaine
Number of subjects: 100
Study 21400792 — intervention group
Group type: COMPARATOR
Intervention: Multi-component general anaesthesia (fentanyl, midazolam, propofol, rocuronium, artificial lung ventilation)
Number of subjects: 100
Study 17885008 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy protein isolate (SPI+) (107 mg isoflavones/d)
Number of subjects: 58
Study 17885008 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-washed soy protein isolate (SPI-) (<6 mg isoflavones/d)
Number of subjects: 58
Study 17885008 — intervention group
Group type: COMPARATOR
Intervention: Milk protein isolate (MPI)
Number of subjects: 58
Study 16329054 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicloabak (diclofenac sodium 0.1% eyedrops without preservative)
Number of subjects: 194
Study 16329054 — intervention group
Group type: COMPARATOR
Intervention: Preserved diclofenac (diclofenac sodium 0.1% eyedrops with sodium merthiolate)
Number of subjects: 194
Study 11973191 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 30
Study 11973191 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 30
Study 9465848 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg once daily, increased to 10 mg if necessary)
Number of subjects: 19193
Study 7615109 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 100
Study 7615109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7615109 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA)
Number of subjects: 100
Study 2118272 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy for 4 months
Number of subjects: 22
Study 2118272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22